Patient P-01332
Therapy response
Stable
Tolerance
Deteriorating
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
96%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S14
- Day 31 NP-02 recommended — Dietary Support Protocol NP-02
- Day 32 Patient accepted — Started NP-02 in the companion
- Day 42 GI symptom burden −23% vs expected — Dietary Support Protocol NP-02
- Day 44 SC-12 recommended — Supportive Compound SC-12
- Day 45 Patient declined — Not now
- Day 48 Tolerance state changed — Unstable → Improving
- Day 53 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 57 GI-04 recommended — GI Support Protocol GI-04
- Day 58 Patient declined — Not now
What changed?
Trajectory began diverging from predicted response on Day 53.
Primary contributors, last 14 days
- Inflammatory activity+13
- Toxicity+13
- GI instability+11
- Treatment adherence-7
What helped?
- Dietary Support Protocol NP-02Day 31Result: symptom burden −23%
- Supportive Compound SC-12Day 44Declined by patient
- GI Support Protocol GI-04Day 57Declined by patient
LIFE OS recommendation
GI Support Protocol GI-04
92%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 83% showed improvement
- median effect visible after 8 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 65 and rising
- WearableSleep 5.3 h, below personal baseline
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 34/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Autonomic recovery ↓45
- WearableResting HR 81 bpm
- WearableShort sleep window
- Inflammatory signalling ↑40
- BloodInflammatory load index 61
- WearableHRV 20 ms, trending down
- Drug metabolism and exposure ↑20
- BloodToxicity index 48
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 2.8 · butyrate capacity 34/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 22 ms
- Sleep
- 5.6 h
- Steps
- 7,753
- Resting HR
- 82 bpm
Daily log: GI score 65, nutritional resilience 40, adherence 43.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- Keep the current walking rhythm
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01872 | 58% | S14 | NP-02 | improved | 47 |
| P-01409 | 57% | S14 | SC-12 | improved | 41 |
| P-01786 | 54% | S07 | ME-01 | improved | 46 |
| P-01496 | 53% | S14 | SC-12 | improved | 46 |
| P-01554 | 53% | S05 | GI-04 | improved | 47 |
| P-01692 | 52% | S14 | NP-02 | improved | 49 |
| P-01822 | 52% | S14 | — | — | 37 |
| P-01462 | 51% | S14 | NP-02 | improved | 47 |
| P-01810 | 51% | S05 | NP-02 | improved | 43 |
| P-01393 | 50% | S14 | GI-04 | improved | 53 |
| P-01834 | 50% | S14 | NP-02 | improved | 44 |
| P-01398 | 49% | S14 | NP-02 | improved | 47 |